DEEP RESEARCH · GENOME & COMPANY
Genome & Company Deep Dive: From Microbiome to ADC
Revaluing the platform through GEN-001 data, GNOCLE, and the Debio 0633 out-license
0. Bottom line first
Genome & Company should no longer be viewed only as a pure microbiome drug developer. GEN-001 Phase 2 data is a validation card from the older platform, while future value is more tied to novel-target antibody and ADC development through the patient-data-driven GNOCLE platform.
1. Industry background: microbiome immuno-oncology
Official fact: The microbiome means microbial communities and their genetic information in a given environment, and the gut microbiome is closely tied to the immune system. The source states that the global microbiome therapeutics market is expected to grow from about US$250M in 2025 to about US$3.4B in 2034, a 33.67% CAGR.
Interpretation: The moat has moved from simply discovering strains to proving mechanisms, engineering patient-specific approaches, and building data-driven platforms. Clinical data and omics capabilities matter more than a list of strains.
2. Core asset: GNOCLE platform
Genome & Company’s GNOCLE platform starts from patient clinical data through a Bed-to-Bench approach. The source describes a library of more than 10,000 cancer-patient tissue and microbiome clinical samples, analyzed through multi-omics.
10,000+ samples
Cancer tissue and microbiome clinical samples serve as the starting point for target discovery.
Bed-to-Bench
The platform prioritizes targets observed in patient data rather than lab-only hypotheses.
Microbiome + ADC
The same discovery engine extends from GEN-001 to novel-target antibodies and ADCs such as GENA-104 and Debio 0633.
3. GEN-001: legacy asset and validation card
| Metric | GEN-001 combination | Comparator | Meaning |
|---|---|---|---|
| Setting | 3L+ gastric cancer | 3L+ standard of care | Large unmet need |
| ORR | 19% | 4% | About five times higher response rate |
| mOS | 7.79 months | 5.7 months | More than two months of overall-survival improvement |
| mPFS | 1.71 months | 2.0 months | Requires immuno-oncology-style responder/non-responder interpretation |
Interpretation: GEN-001 is more likely to be used as an out-licensing card than as a large self-funded follow-on program. Its deeper importance is proving that GNOCLE can produce real drug candidates.
4. ADC pivot and financial risk
Official fact: GENA-104 is described as a CNTN4-targeting antibody and ADC. Debio 0633 is one ADC version of GENA-104 and was licensed to Switzerland’s Debiopharm in May 2024. The source also states that the company raised about KRW 54B, or US$40M, through its U.S. subsidiary in April 2025.
- Risk: as an R&D biotech, operating cash flow remains structurally negative
- Overhang: about KRW 34.3B of CPS issued in August 2022 at KRW 18,350 per share
- Strategic shift: the early termination of the GEN-001 biliary-tract-cancer trial signals lower large-scale microbiome spending and greater ADC focus
5. My checklist
- Whether GEN-001 is out-licensed and on what terms
- Timing of GENA-104 ADC Phase 1 entry
- Additional GNOCLE-based ADC out-licenses after Debio 0633
- Use of U.S. subsidiary funding and cash-burn pace
- CPS overhang and possible future financing